Latest & greatest articles for nsaids

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on nsaids or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on nsaids and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for nsaids

101. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. (Abstract)

NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. NSAIDs are widely applied to treat cancer pain and are frequently combined with opioids in combination preparations for this purpose. However, it is unclear which agent is most clinically efficacious for relieving cancer-related pain, or even what may be the additional benefit of combining an NSAID with an opioid in this setting.To assess the effects of NSAIDs, alone or combined with opioids, for the treatment of cancer (...) pain.We searched the Cochrane Central Register of Controlled Trials (Issue 2, 2002), MEDLINE (January 1966 to March 2003), EMBASE (January 1980 to December 2001), LILACS (January 1984 to December 2001) and reference list of articles.Randomized controlled trials and controlled clinical trials that compared NSAID versus placebo; NSAID versus NSAID; NSAID versus NSAID plus opioid; opioid versus opioid plus NSAID; or NSAID versus opioid.Two reviewers independently assessed trial quality and extracted data

2005 Cochrane

102. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users

Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

103. Effect of preoperative Cox-II-selective NSAIDs (coxibs) on postoperative outcomes: a systematic review of randomized studies

Effect of preoperative Cox-II-selective NSAIDs (coxibs) on postoperative outcomes: a systematic review of randomized studies Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

104. Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis

Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors (...) in the treatment of rheumatoid arthritis Yun H R, Bae S C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of non-steroidal anti-inflammatory agents (NSAIDs) with and without concomitant therapy to prevent

2005 NHS Economic Evaluation Database.

105. Nonsteroidal anti-inflammatory drugs (NSAIDs) versus opioids for acute renal colic. (Abstract)

Nonsteroidal anti-inflammatory drugs (NSAIDs) versus opioids for acute renal colic. Renal colic is a common cause of acute severe pain. Both opioids and nonsteroidal anti-inflammatory drugs (NSAIDs) are recommended for treatment, but the relative efficacy of these drugs is uncertain.To examine the benefits and disadvantages of NSAIDs and opioids for the management of pain in acute renal colic.We searched the Cochrane Renal Group's specialised register (May 2003), the Cochrane Central Register (...) of Randomised Controlled Trials (CENTRAL - The Cochrane Library issue 2, 2003), MEDLINE (1966 - 31 January 2003), EMBASE (1980 - 31 January 2003) and handsearched reference lists of retrieved articles.Randomised controlled trials (RCTs) comparing any opioid with any NSAID, regardless of dose or route of administration were included.Data was extracted and quality assessed independently by two reviewers, with differences resolved by discussion. Dichotomous outcomes are reported as relative risk (RR

2004 Cochrane

106. Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas. (Abstract)

Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas. There is evidence from experimental animals studies, prospective and retrospective observational studies that nonsteroidal anti-inflammatory drugs (NSAIDS) may reduce the development of sporadic colorectal adenomas (CRAs) and cancer (CRC) and may induce the regression of adenomas in familial adenomatous polyposis (FAP).To conduct a systematic review to determine the effect of NSAIDS

2004 Cochrane

107. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK

Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK Moore A, Phillips C, Hunsche E, Pellissier J, Crespi S Record Status (...) was derived from a synthesis of completed studies. Modelling A decision tree model was used to assess the expected costs and consequences of ETO, compared with different options of non-selective NSAIDs, in a hypothetical cohort of 10,000 patients. GI events, major (clinically evident gastroduodenal perforations, symptomatic gastroduodenal ulcers or upper GI bleeding) and minor (those that could lead to treatment), were calculated and entered into the model to derive the total costs associated with each

2004 NHS Economic Evaluation Database.

108. Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs

Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs Henry D, McGettigan P CRD summary This review assessed the risk of serious gastrointestinal complications with non-steroidal anti-inflammatory drugs (NSAIDs). The authors concluded that, at low doses, the risk is lower with ibuprofen than with other NSAIDs. Wide variation (...) in the estimate of risk between different studies of the same drugs, which the authors were unable to explain, casts doubt on the reliability of the conclusion. Authors' objectives The objectives were three-fold: to update previous systematic reviews; to determine the effects of non-steroidal anti-inflammatory drugs (NSAIDs) on the risk of serious gastrointestinal complications; and to examine the place of drug dose in explaining the variation in this risk. Searching MEDLINE, EMBASE, the Cochrane Library

2003 DARE.

109. Non-steroidal anti-inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults. (Abstract)

Non-steroidal anti-inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults. Lateral elbow pain, or tennis elbow, is a common condition causing pain in the elbow and forearm and lack of strength and function of the elbow and wrist. It is often treated with non-steroidal anti-inflammatory drugs (NSAIDs), either orally or by topical application.To assess effectiveness of NSAIDs (oral or topical) in the treatment of adults with lateral elbow pain with respect to symptom (pain (...) ) reduction, improvement in function, grip strength and adverse effects.We searched the Musculoskeletal Review Group's trials register database, the Cochrane Clinical Trials Register (Cochrane Library issue 2, 2001), MEDLINE, CINAHL, EMBASE and SCISEARCH up to June 2001.Randomised and pseudo randomised trials in all languages of NSAIDs (oral or topical) compared to placebo or another intervention, or comparing two NSAIDs (oral or topical) to each other, in adults with lateral elbow pain (tennis elbow

2002 Cochrane

110. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors

Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors Zhao S Z, Burke T A, Whelton A, von Allmen H (...) (NSAIDS). No further details of the drugs (producer), or the doses used, were reported. Celecoxib was the comparator. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with stable hypertension who had recently begun therapy with celecoxib, rofecoxib, ibuprofen, diclofenac, or naproxen. Eligible patients were those who had not filled a prescription for a non-specific NSAID or COX-2-specific inhibitor within

2002 NHS Economic Evaluation Database.

111. Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: a qualitative review

Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: a qualitative review Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: a qualitative review Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: a qualitative review Hyllested M, Jones S, Pedersen J L, Kehlet H Authors' objectives To compare the safety and efficacy of paracetamol, non-steroidal anti (...) -inflammatory drugs (NSAIDs), and their combinations in post-operative pain management. Searching MEDLINE (from 1966 to January 2001) and the Cochrane Library (January 2001) were searched for articles published in full in the English language. The search strategy used pain terms combined with the keywords 'paracetamol', 'acetaminophen', 'proparacetamol', 'non-steroidal anti-inflammatory drugs (NSAID)', or individual drug names. The reference lists from identified studies were also examined. Study selection

2002 DARE.

112. Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: a decision analysis

Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: a decision analysis Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: a decision analysis Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: a decision analysis Fendrick A M, Bandekar R R, Chernew M E, Scheiman J M Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of nonsteroidal anti-inflammatory drugs (NSAIDs) in the prevention of NSAID gastropathy. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The hypothetical population comprised long-term users of NSAIDs without risk factors

2002 NHS Economic Evaluation Database.

113. Helicobacter pylori screening for individuals requiring chronic NSAID therapy: a decision analysis

Helicobacter pylori screening for individuals requiring chronic NSAID therapy: a decision analysis Helicobacter pylori screening for individuals requiring chronic NSAID therapy: a decision analysis Helicobacter pylori screening for individuals requiring chronic NSAID therapy: a decision analysis Scheiman J M, Bandekar R R, Chernew M E, Fendrick A M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of Helicobacter pylori (Hp) screening for chronic users of non-steroidal anti-inflammatory drugs (NSAIDs). Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population The study population included all NSAID users at an average risk of peptic ulcer disease. More detailed characteristics

2001 NHS Economic Evaluation Database.

114. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective

Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective Marshall J K, Pellissier J M, Attard C L, Kong S X, Marentette M (...) published over a number of years. The price year was 1999. Source of effectiveness data The effectiveness evidence came from a review of the literature and authors' assumptions. Modelling A decision tree model was constructed to compare the costs and benefits of the two alternative treatments reflecting practice in the Canadian setting. The model referred to a hypothetical cohort of patients with OA who were treated with either rofecoxib or NSAIDs over a period of one year. Patients could develop GI

2001 NHS Economic Evaluation Database.

115. Local infiltration with NSAIDs for postoperative analgesia: evidence for a peripheral analgesic action

Local infiltration with NSAIDs for postoperative analgesia: evidence for a peripheral analgesic action Local infiltration with NSAIDs for postoperative analgesia: evidence for a peripheral analgesic action Local infiltration with NSAIDs for postoperative analgesia: evidence for a peripheral analgesic action Romsing J, Moiniche S, Ostergaard D, Dahl JB Authors' objectives To investigate the evidence for a peripheral analgesic effect of local infiltration with non-steroidal anti-inflammatory (...) drugs (NSAIDs) in post-operative pain. Searching MEDLINE was searched from 1966 to September 1999, EMBASE from 1989 to August 1999, and the Cochrane library in 1999, using the search terms 'NSAID', 'non-steroidal anti-inflammatory drug', individual drug names, 'postoperative pain', 'local infiltration', 'intra-articular', 'regional' and 'surgical site'. There were no restrictions on publication language. Additional studies were identified from the references lists of retrieved reports. Abstracts

2000 DARE.

116. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use

Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use Tramer M R, Moore R A, Reynolds D J, McQuay H J Authors' objectives To estimate the incidence of death from (...) gastroduodenal complications with chronic use of non-steroidal anti-inflammatory drugs (NSAIDs). Searching MEDLINE and EMBASE (up to December 1996) were searched for articles published in any language, using the following free text terms either alone or in combination: 'non-steroidal anti-inflammatory drug', 'aspirin', 'ulcer', 'bleeding', 'haemorrhage', 'perforation' and 'death'. Additional studies were identified by handsearching reference lists from retrieved reports, review articles on NSAIDs, relevant

2000 DARE.

117. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. (Abstract)

A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. Suppressing acid secretion is thought o reduce the risk of ulcers associated with regular use of nonsteroidal antiinflammatory drugs (NSAIDs), but the best means of accomplishing this is uncertain.We studied 541 patients who required continuous treatment with NSAIDs and who (...) of omeprazole). The rates of healing of all types of lesions were higher with omeprazole than with ranitidine. During maintenance therapy, the estimated proportion of patients in remission at the end of six months was 72 percent in the omeprazole group and 59 percent in the ranitidine group. The rates of adverse events were similar between groups during both phases. Both medications were well tolerated.In patients with regular use of NSAIDs, omeprazole healed and prevented ulcers more effectively than did

1998 NEJM Controlled trial quality: uncertain

118. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. (Abstract)

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. Misoprostol is effective for ulcers associated with the use of nonsteroidal antiinflammatory drugs (NSAIDs) but is often poorly tolerated because of diarrhea and abdominal pain. We compared the efficacy of omeprazole and misoprostol in healing and preventing ulcers associated with NSAIDs.In a double-blind (...) study, we randomly assigned 935 patients who required continuous NSAID therapy and who had ulcers or more than 10 erosions in the stomach or duodenum (or both) to receive 20 mg or 40 mg of omeprazole orally in the morning or 200 microg of misoprostol orally four times daily. Patients were treated for four weeks or, in the absence of healing, eight weeks. Treatment success was defined as the absence of ulcers and the presence of fewer than five erosions at each site and not more than mild dyspepsia

1998 NEJM Controlled trial quality: predicted high

119. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. (Abstract)

Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. The effect of Helicobacter pylori in patients receiving non-steroidal anti-inflammatory drugs (NSAIDs) is unclear. We investigated the effects of H. pylori eradication in patients with current or previous peptic ulceration, dyspepsia, or both who continued to use NSAIDs.285 patients were randomly assigned (...) omeprazole 20 mg, amoxycillin 1000 mg, and clarithromycin 500 mg, twice daily (n=142, H. pylori eradication treatment), or omeprazole with placebo antibiotics (n=143, controls) for 1 week. All patients received omeprazole 20 mg once daily for 3 weeks until endoscopy, and, if the ulcer was not healed, 40 mg once daily until repeat endoscopy at 8 weeks. Ulcer-free patients with mild dyspepsia continued NSAIDs but not antiulcer treatment. We investigated ulcers with endoscopy at 1, 3, and 6 months

1998 Lancet Controlled trial quality: predicted high

120. Choice of NSAID and management strategy in rheumatoid arthritis and osteoarthritis: the impact on costs and outcomes in the UK

Choice of NSAID and management strategy in rheumatoid arthritis and osteoarthritis: the impact on costs and outcomes in the UK Choice of NSAID and management strategy in rheumatoid arthritis and osteoarthritis: the impact on costs and outcomes in the UK Choice of NSAID and management strategy in rheumatoid arthritis and osteoarthritis: the impact on costs and outcomes in the UK McCabe C J, Akehurst R L, Kirsch J, Whitfield M, Backhouse M, Woolf A D, Scott D L, Emery P, Haslock I Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Non-steroidal anti-inflammatory drugs (NSAIDs) for the management of rheumatoid arthritis and osteoarthritis: nabumetone (between 1,000 and 2,000 mg per day), diclofenac (100-200 mg per day), ibuprofen (1,200

1998 NHS Economic Evaluation Database.